Sino Biopharm Wins Breakthrough Therapy Status for Graft-Versus-Host Disease Drug in China
MT Newswires Live
Aug 06
Sino Biopharmaceutical's (HKG:1177) rovadicitinib tablet has been included in the breakthrough therapeutic designation process by China's National Medical Products Administration for the treatment of chronic graft-versus-host disease, a Wednesday Hong Kong bourse filing said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.